Journal of Nutrition OpenSOurce Diets- www.ResearchDiets.com

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Nutrition Vol. 126 No. 1 January 1996, pp. 176-182
Copyright
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by King, R. A.
Right arrow Articles by Head, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by King, R. A.
Right arrow Articles by Head, R. J.

Absorption and Excretion of the Soy Isoflavone Genistein in Rats1

Roger A. King2, Jessica L. Broadbent* and Richard J. Head*

CSIRO Division of Human Nutrition, Adelaide, South Australia 5000 * Department of Clinical and Experimental Pharmacology, University of Adelaide, South Australia 5000

Rodent models have been used to study the anticarcinogenic properties of the soy isoflavones, particularly genistein, but there is little information regarding the pharmacokinetics of the absorption and excretion of genistein. In this study, rats were given a single oral dose of genistein (20 mg/kg body weight) or an equivalent dose of its glycone forms, as an isoflavone-rich soy extract. Concentrations of genistein were measured in plasma, urine and feces at intervals up to 48 h after dosing. Plasma genistein concentration at 2 h after dosing was 11.0 ± 2.3 µmol/L in genistein-treated rats compared with 4.93 ± 0.22 µmol/L (P = 0.025) in soy extract-treated rats, but there were no significant differences at 8 h and later times. The mean urinary excretion rate during the first 2 h after dosing was more than 10 times higher in the genistein group compared with the soy extract group (0.27 ± 0.08 µmol/h and 0.020 ± 0.011 µmol/h, respectively, P = 0.017) but the percentage of dose recovered in urine over 48 h was not different between groups (19.9 ± 2.4% genistein treated; 17.5 ± 1.1% soy extract treated). There were no significant differences between groups in the recovery of genistein in feces (21.9 ± 2.8% and 21.1 ± 2.5% of dose, respectively). Only 6.1 ± 0.9% of the daidzein from the soy extract was recovered in the feces. The results suggest that the extent of absorption of genistein is similar for the glycone and aglycone forms. Although higher initial plasma concentrations may be achieved with the aglycone, similar long-term concentrations exist for both forms of isoflavone.


KEY WORDS: • genistein • daidzein • pharmacokinetics • rats • soy

1 The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

2 To whom correspondence should be addressed.

Manuscript received 10 July 1995. Revision accepted 16 August 1995.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]